NanoDx Prepares for Point-of-Care Platform Commercialization With TBI, COVID Tests

Sep 9, 2022

NEW YORK – After finalizing its manufacturing strategy, point-of-care diagnostic firm NanoDx is working to commercialize its tramautic brain injury (TBI) and COVID-19 tests. The firm’s reagent-less NanoDx System, which uses electrical currents to detect...

NanoDx and SkyWater Announce First Commercially Ready Nano Biosensor to Yield Protein Response

Aug 25, 2022

NanoDx, Inc., a developer of breakthrough point-of-care diagnostic solutions and SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, today announced the first commercially ready nano biosensor to yield a protein response. The unique size...

George J. Serafin Joins NanoDx, Inc. as President & CEO

Jun 15, 2022

Boston, MA – June 15, 2022 – NanoDx, Inc., is a privately held medical device company developing rapid, near-patient, point-of-care, in-vitro diagnostic solutions leveraging a first-of-its-kind nanowire biosensor technology to improve patient outcomes and reduce...

NanoDx, Inc. Promotes Mike Sampson to Chief Commercial Officer Position

Jan 10, 2022

Boston, MA – January 10, 2022 – NanoDx, Inc., a privately held medical device company developing rapid, point-of-care diagnostic solutions that address unmet market needs and improve patient outcomes while reducing healthcare costs. The company’s...

Dr John E. Kelly joining NanoDx, Inc as Technical and Strategic Advisor to the Board of Directors

Jan 5, 2022

It is immense pleasure that we announce the Dr. John E. Kelly, former Executive Vice President of IBM, will be joining NanoDx as a Technical and Strategic Advisor to the Board of Directors. Dr. Kelly will provide technical advice and assistance to the Company...